Arvinas (ARVN) Barclays 28th Annual Global Healthcare Conference summary

Strategic overview and pipeline progress

• Four programs are now in phase I, marking a shift to a clinical-stage focus, with a new AR program for Kennedy's disease recently initiated and an HPK1 degrader expected to enter phase I by year-end.

• Vepdegestrant, an ER degrader, has positive pivotal data and an NDA filed with a PDUFA date in early June; partnership discussions are progressing and expected to conclude before the regulatory decision.

• The company is prioritizing differentiation in its pipeline, evaluating investment focus, and remains open to partnerships to advance programs.

• By 2026, clinical data for three of the four phase I programs are anticipated, with leadership emphasizing milestone-driven growth.

LRRK2 and neurodegenerative disease programs

• LRRK2 degrader (ARV-102) targets neurodegenerative diseases, with phase I data showing blood-brain barrier penetration, safety, and significant CSF LRRK2 reduction.

• Upcoming data at the ADPD meeting will include results in Parkinson's disease patients, focusing on safety, biomarker engagement, and pathway differentiation.

• The program demonstrates full pathway engagement in CSF, a differentiator from competitors, and aims to start a phase I-B trial in PSP in the first half of the year.

• PSP is a rare, rapidly progressing, and devastating disease with a clear clinical rating scale for trials; a registrational study could begin by year-end pending regulatory steps.

Oncology pipeline: KRAS and BCL6 degraders

• KRAS G12D degrader (ARV-806) is highly potent, removes the oncoprotein, and avoids immunosuppressive effects seen with some inhibitors; phase I is fully enrolled with data expected this year.

• The pan-KRAS degrader shows efficacy in overcoming resistance due to KRAS amplification, with preclinical data presented at a recent conference.

• Future development of KRAS programs may involve partnerships, especially as they move into later-stage and combination studies.

• BCL6 degrader (ARV-393) phase I data is expected in the second half of the year, with a combination study with glofitamab starting soon; the program includes T-cell lymphoma patients for broader differentiation.